Although these studies indicate neutralization of ICOSL can help ameliorate symptoms associated with SLE, the therapeutic potential of disrupting ICOS signaling may extend beyond TD humoral responses. This evidence concerns the gene ICOSLG and systemic lupus erythematosus.